New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

Bristol-Myers Squibb Company (NYSE:BMY) today announced that new data on NULOJIX (belatacept) will be presented at the European Society for Organ Transplantation (ESOT) Congress on September 4 -7, 2011 in Glasgow, Scotland, United Kingdom. In total, 15 abstracts from company-sponsored and supported studies will be presented during the congress, including data from the pivotal trials that supported the recent European Commission Marketing Authorization and U.S. Food and Drug Administration approval of NULOJIX in June, 2011 for the prophylaxis of organ rejection in adult EBV seropositive patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids. The breadth of data being highlighted at this key congress reinforces the company's commitment to innovate in the areas of serious disease and biologics drug development.

New data on NULOJIX being presented for the first time include:

  • Donor Sub-type Analysis of Three-year Outcomes from a Phase III Study of Belatacept in Recipients of Extended Criteria Donor Kidneys (BENEFIT-EXT Trial)
  • Outcomes at 3 Years in Kidney Transplant Recipients with Pre-Transplant Diabetes from Two Phase 3 Belatacept Studies
  • Evaluation of Donor-Specific Antibodies in Kidney Transplant Patients Treated with Belatacept- or Cyclosporine-Based Immunosuppression in BENEFIT and BENEFIT-EXT
  • A Comparison of the Peripheral Blood mRNA Transcriptional Profile of Belatacept- and Cyclosporine-treated Renal Transplant Patients

"The clinical data on NULOJIX being presented at the European Society for Organ Transplantation Congress will add to the body of research that supported its U.S. and European approvals," said Brian Daniels, M.D., senior vice president, Global Development and Medical Affairs, Bristol-Myers Squibb. "BMS is committed to work with the transplant community to broaden our understanding of the efficacy and safety profile for NULOJIX which can enable patients and physicians to make informed decisions about treatment options."

Source:

 Bristol-Myers Squibb

Comments

  1. alev keskin alev keskin Turkey says:

    When will we Turkish renal transplant patients suffering from CNI nephrotoxicity even at very low doses will be able to see the beşatacept in our market. We are looling forward to it before our renal function permenantly deteriorates due to CNI nephrotoxity.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Kidney transplants: Volume of services correlated with quality of treatment outcomes